<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00683826</url>
  </required_header>
  <id_info>
    <org_study_id>AAAC6762</org_study_id>
    <nct_id>NCT00683826</nct_id>
  </id_info>
  <brief_title>The Effects of Leucine on Body Weight</brief_title>
  <official_title>Effects of Leucine Supplement on Body Weight and Cardiometabolic Changes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Protein-rich diets appear to show some benefits in promoting weight loss. It is thought that
      increased intake of leucine may account for some of this effect. This study is designed to
      assess whether any of the beneficial effects of dietary leucine supplementation observed in
      mice also apply to humans.

      Specifically, our team would like to determine whether oral leucine supplementation in
      overweight/obese humans increases metabolic rate, reduces body weight, improves glucose
      utilization and/or, reduces circulating fat levels in the blood. We hope that the results
      obtained from this pilot study will highlight the specific aspects of metabolic improvement
      associated with increased daily leucine intake. This study will should provide data that can
      be used to design more definitive trials with regard to dietary leucine supplementation.

      Hypothesis

      This pilot study is designed to accomplish the following two goals:

        1. to assess whether any of the beneficial effects of dietary leucine supplementation
           observed in mice also apply in humans. Specifically, we want to determine whether oral
           leucine supplementation in overweight/obese individuals' increases basal metabolic rate,
           reduces body weight, improves glucose tolerance and/or insulin sensitivity, and/or
           reduces circulating Low-density Lipoprotein (LDL)-cholesterol levels.

        2. To provide data that can be used to design more definitive trials with regard to dietary
           leucine supplementation.

      We hope that the results obtained from this pilot study will highlight the specific aspects
      of metabolic improvement associated with increased daily leucine intake. This would in turn
      lead to more rigorous clinical trials involving larger sample sizes, and with diverse
      populations of different gender, age, and ethnic groups. Future trials may also be directed
      to determine minimal doses and durations of leucine supplementation that are capable of
      achieving clinically significant improvement in the cardio-metabolic risk profile in people.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects on Weight</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight</measure>
    <time_frame>at the end of each study treatment arm (six weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Energy Expenditure</measure>
    <time_frame>will be measure at the end of each treatment period (6 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Overweight</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>L-Leucine 4grams</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This will be a triple arm design where subjects will be randomized into three groups. Arm #1 will be 4g of Leucine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L-Leucine 8 grams</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm number two of the study will be a dose of Leucine of 8g.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L-Leucine 0 grams</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The third arm of the study will be composed of a control drink with no leucine in it.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-Leucine 8gr</intervention_name>
    <description>Supplementation in the form of a liquid meal (premixed leucine powder solutions with flavor made by the Bionutrition Unit of the Irving Insitute for Clinical and Translational Research (IICTR)). Dosing of leucine will be a combination of 2 ounces of liquid per 1 gm of leucine. L-leucine was purchased (FCC quality) from Spectrum Chemical,California. Certificate of analysis enclosed (99.89% leucine).Liquid meal preparation: Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. Each drink will be individually prepared with 8 grams of leucine.</description>
    <arm_group_label>L-Leucine 8 grams</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Liquid meal</intervention_name>
    <description>Liquid meal preparation (contents): Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. The placebo group will have the same drinks listed above with no leucine incorporated.</description>
    <arm_group_label>L-Leucine 4grams</arm_group_label>
    <arm_group_label>L-Leucine 8 grams</arm_group_label>
    <arm_group_label>L-Leucine 0 grams</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-Leucine 4g</intervention_name>
    <description>Supplementation in the form of a liquid meal (premixed leucine powder solutions with flavor made by the Bionutrition Unit of the Irving Insitute for Clinical and Translational Research (IICTR)). Dosing of leucine will be a combination of 2 ounces of liquid per 1 gm of leucine. L-leucine was purchased (FCC quality) from Spectrum Chemical,California. Certificate of analysis enclosed (99.89% leucine).Liquid meal preparation: Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. Each drink will be individually prepared with 4 grams of leucine.</description>
    <arm_group_label>L-Leucine 4grams</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-65 year old overweight/obese

          -  healthy men and women

          -  Body Mass Index (BMI) of 28-35

        Exclusion Criteria:

          -  unusual or extreme dietary or exercise habits

          -  daily leucine supplement use

          -  inability to follow instructions to drink liquid meals

          -  type 1 diabetes or type 2 diabetes on drug treatment(diet controlled diabetics will be
             enrolled after consulting with their treating physicians)

          -  hypothyroidism or hyperthyroidism

          -  chronic wasting diseases (Acquired Immune Deficiency Syndrome (AIDS), cancers,
             cirrhosis, renal failure, Chronic Obstructive Pulmonary Disease (COPD), heart failure)

          -  drug or alcohol abuse

          -  tobacco smoker within the past 6 months

          -  pregnancy or lactating

          -  use of medications known to affect carbohydrate or lipid metabolism, satiety, or
             hunger

          -  anemia

          -  abnormal liver function tests (LFTs)

          -  women who are of child bearing age without adequate birth control modality
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry Ginsberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2008</study_first_submitted>
  <study_first_submitted_qc>May 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2008</study_first_posted>
  <results_first_submitted>March 1, 2011</results_first_submitted>
  <results_first_submitted_qc>July 12, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 9, 2011</results_first_posted>
  <last_update_submitted>March 4, 2013</last_update_submitted>
  <last_update_submitted_qc>March 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Henry N. Ginsberg</investigator_full_name>
    <investigator_title>Herbert and Florence Irving Professor of Medicine; Director - Irving Institute for Clinical &amp; Translational Research</investigator_title>
  </responsible_party>
  <keyword>Leucine</keyword>
  <keyword>Weight Loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Body Weight</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment was completed. All subjects were recruited from the surrounding neighborhood and affiliates of Columbia University Medical Center (CUMC).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
          <description>This will be a three-way crossover design, where subjects will be randomized into three groups. All subjects will receive all interventions (0g leucine, 4g leucine, 8g leucine) in a randomized order.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>0g Leucine</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>8g Leucine</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>4g Leucine</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Leucine 4 Grams</title>
          <description>Initial intervention.</description>
        </group>
        <group group_id="B2">
          <title>Leucine 8 Grams</title>
          <description>Initial intervention.</description>
        </group>
        <group group_id="B3">
          <title>Leucine 0 Grams-control</title>
          <description>Initial intervention.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35" spread="7"/>
                    <measurement group_id="B2" value="40" spread="7"/>
                    <measurement group_id="B3" value="45" spread="7"/>
                    <measurement group_id="B4" value="40" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effects on Weight</title>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Leucine 4 Grams</title>
            <description>This will be a triple arm design where subjects will be randomized into three groups. Arm #1 will be 4g of Leucine.</description>
          </group>
          <group group_id="O2">
            <title>Leucine 8 Grams</title>
            <description>Arm number two of the study will be a dose of Leucine of 8g.</description>
          </group>
          <group group_id="O3">
            <title>Leucine 0 Grams-control</title>
            <description>The third arm of the study will be composed of a control drink with no leucine in it.</description>
          </group>
        </group_list>
        <measure>
          <title>Effects on Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.4" spread="16.8"/>
                    <measurement group_id="O2" value="91.7" spread="17.2"/>
                    <measurement group_id="O3" value="91.9" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Energy Expenditure</title>
        <time_frame>will be measure at the end of each treatment period (6 weeks)</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Weight</title>
        <time_frame>at the end of each study treatment arm (six weeks)</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Leucine 4 Grams</title>
          <description>This will be a triple arm design where subjects will be randomized into three groups. Arm #1 will be 4g of Leucine.</description>
        </group>
        <group group_id="E2">
          <title>Leucine 8 Grams</title>
          <description>Arm number two of the study will be a dose of Leucine of 8g.</description>
        </group>
        <group group_id="E3">
          <title>Leucine 0 Grams-control</title>
          <description>The third arm of the study will be composed of a control drink with no leucine in it.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Henry N. Ginsberg MD, Gissette Reyes Soffer MD</name_or_title>
      <organization>Columbia University Medical Center</organization>
      <phone>2123059298</phone>
      <email>gr2104@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

